Quantum Genomics Enrolls First Patient in Its Pivotal Phase III FRESH Trial of Firibastat in Difficult-to-treat and Resistant Hypertension The FRESH study is a randomized, double-blind, placebo-controlled pivotal phase III study, which will be conducted in approximately 70 hospitals worldwide and enroll 502 patients with difficult-to-treat or resistant hypertension. Read the press release Previous Post (p) Quantum Genomics Announces Interim Analysis from Study of Firibastat in Renal Failure Patients Next Post (n) Quantum Genomics to give an exclusive license for firibastat in South-East Asia, Australia and New Zealand